The Biological Disease‐Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta‐Analysis
Suiyuan Hu(Peking University), Linong Ji(Peking University), Xiaoling Cai(Peking University), Fang Lv(Liaoning Normal University), Chu Lin(Peking University), Lin Nie(Airport Shunyi District Hospital), Xingyun Zhu(Peking University)
Cited by 28
Related Papers
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
|Diabetologia|2020|373
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
|Nature Medicine|2024|152
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128